Your shopping cart is currently empty

Edaglitazone (R-483) is an orally active, selective and potent PPARγ agonist showing affinity for both PPARα and PPARγ. Edaglitazone displays antiplatelet activity and can be used in studies of diabetes mellitus and obesity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $519 | 35 days | 35 days |
| Description | Edaglitazone (R-483) is an orally active, selective and potent PPARγ agonist showing affinity for both PPARα and PPARγ. Edaglitazone displays antiplatelet activity and can be used in studies of diabetes mellitus and obesity. |
| Targets&IC50 | PPARα:1053 nM (EC50), PPARγ:35.6 nM (EC50) |
| In vitro | METHODS: To elucidate the mechanism of the antiplatelet effect of edaglitazone, platelet cAMP levels were assessed using edaglitazone (3, 6, and 12 μM), Consistent with the aggregation assay, RESULTS: Edaglitazone increased platelet cAMP levels in a concentration-dependent manner, suggesting that its antiplatelet effect is partly mediated by the regulation of cAMP levels. [1] |
| Synonyms | R-483, Edaglitazone sodium, BM-13.1258 |
| Molecular Weight | 464.56 |
| Formula | C24H20N2O4S2 |
| Cas No. | 213411-83-7 |
| Smiles | O=C1SC(C(=O)N1)CC2=CC=C(OCCC=3N=C(OC3C)C=4C=CC=CC4)C=5C=CSC52 |
| Relative Density. | 1.374 g/cm3 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.